BONOMO SARA MARIA

Jemma, A., Ardizzoia, A., Villa, C., Bonomo, S., Mauri, M., Reale, C., et al. (2025). TIMP1 Overexpression in Ovarian Cancer Spheroids: Implications for Prognosis, Resistance, and Metastatic Potential. CANCERS, 17(10) [10.3390/cancers17101605]. Dettaglio

Grassilli, E., Cerrito, M., Bonomo, S., Giovannoni, R., Conconi, D., and Lavitrano, M. (2023). Targeting p65BTK for treating solid cancers. Intervento presentato a: 6th world cancer research, Lisbona. Dettaglio

Grassilli, E., Cerrito, M., Bonomo, S., Giovannoni, R., Conconi, D., Lavitrano, M. (2021). p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 9 [10.3389/fcell.2021.690365]. Dettaglio

Lavitrano, M., Ianzano, L., Bonomo, S., Cialdella, A., Cerrito, M., Pisano, F., et al. (2020). BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers. JOURNAL OF PATHOLOGY, 250(2), 134-147 [10.1002/path.5347]. Dettaglio

Giordano, F., Vaira, V., Cortinovis, D., Bonomo, S., Goedmakers, J., Brena, F., et al. (2019). p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 38(1) [10.1186/s13046-019-1199-7]. Dettaglio